Wall Street brokerages expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to report $70,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aurinia Pharmaceuticals’ earnings. The lowest sales estimate is $30,000.00 and the highest is $100,000.00. Aurinia Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The business is expected to announce its next earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year sales of $370,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $500,000.00. For the next fiscal year, analysts forecast that the business will report sales of $170,000.00, with estimates ranging from $100,000.00 to $300,000.00. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative return on equity of 36.10% and a negative net margin of 7,280.85%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.07 million.

A number of equities research analysts have commented on the stock. BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 15th. Cantor Fitzgerald set a $18.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 1st. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, September 26th. Two analysts have rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $11.79.

NASDAQ AUPH traded up $0.16 on Tuesday, reaching $5.49. 328,900 shares of the stock were exchanged, compared to its average volume of 592,683. Aurinia Pharmaceuticals has a one year low of $4.41 and a one year high of $6.69. The stock has a market cap of $445.39 million, a price-to-earnings ratio of -5.99 and a beta of 2.22.

Several institutional investors have recently added to or reduced their stakes in AUPH. BlackRock Inc. raised its position in shares of Aurinia Pharmaceuticals by 45.2% during the first quarter. BlackRock Inc. now owns 1,045,121 shares of the biotechnology company’s stock valued at $5,424,000 after buying an additional 325,408 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Aurinia Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after buying an additional 105,300 shares during the last quarter. FMR LLC raised its position in shares of Aurinia Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after buying an additional 95,650 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter valued at approximately $276,000. Finally, Ironwood Investment Management LLC raised its position in shares of Aurinia Pharmaceuticals by 18.0% during the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after buying an additional 33,279 shares during the last quarter. Hedge funds and other institutional investors own 24.84% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Further Reading: Asset Allocation Models, Which is Right For You?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.